Literature DB >> 8408474

Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1.

B L Johansson1, A Kernell, S Sjöberg, J Wahren.   

Abstract

The possible influence of C-peptide on renal function and metabolic control in patients with type 1 diabetes was examined in a double blind, randomized study. Nine patients received insulin and equimolar amounts of biosynthetic human C-peptide for 1 month (group 1), and nine were given insulin only (group 2). C-Peptide levels in plasma ranged from 0.3-2.6 nmol/L in group 1 during the study, whereas group 2 had undetectable levels. The urinary excretion of albumin in group 1 was 21 +/- 6 micrograms/min before the study and decreased by 40% and 55% after 2 and 4 weeks, respectively (P < 0.05). No change was seen in group 2. The glomerular filtration rate fell by 6% after 2 and 4 weeks (P < 0.05) in group 1, whereas no change was observed in group 2. Fluorescein leakage across the blood-retinal barrier decreased by 30% in group 1 (P < 0.05) and was unaltered in group 2. Hemoglobin-A1c and fructosamine values decreased by 9-16% in group 1 (P < 0.05), but not in group 2. The findings suggest that administration of C-peptide plus insulin, compared to insulin alone, to type 1 diabetic patients may reduce glomerular permeability and improve metabolic control.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408474     DOI: 10.1210/jcem.77.4.8408474

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells.

Authors:  N M Al-Rasheed; F Meakin; E L Royal; A J Lewington; J Brown; G B Willars; N J Brunskill
Journal:  Diabetologia       Date:  2004-05-26       Impact factor: 10.122

2.  Protective role of adenovirus vector-mediated interleukin-10 gene therapy on endogenous islet β-cells in recent-onset type 1 diabetes in NOD mice.

Authors:  Cheng Li; Lijuan Zhang; Yanyan Chen; Xiaojie Lin; Tang Li
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

3.  Insulin resistance in children with primary nephrotic syndrome and normal renal function.

Authors:  Jiaping Jin; Bo Jin; Songming Huang; Yanggang Yuan; Guixia Ding; Huaying Bao; Ying Chen; Yuan Han; Fei Zhao; Aihua Zhang
Journal:  Pediatr Nephrol       Date:  2012-05-24       Impact factor: 3.714

4.  Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus.

Authors:  T Forst; T Kunt; T Pohlmann; K Goitom; M Engelbach; J Beyer; A Pfützner
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

Review 5.  Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus.

Authors:  Ahmad Ghorbani; Reza Shafiee-Nick
Journal:  World J Diabetes       Date:  2015-02-15

Review 6.  C-peptide: a new potential in the treatment of diabetic nephropathy.

Authors:  J Wahren; K Ekberg; B Samnegård; B L Johansson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

7.  Obesity-related markers and breast cancer in CPS-II Nutrition Cohort.

Authors:  Mia M Gaudet; Alpa V Patel; Lauren R Teras; Juzhong Sun; Peter T Campbell; Victoria L Stevens; Eric J Jacobs; Susan M Gapstur
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

8.  Proinsulin C-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects.

Authors:  J Shafqat; E Melles; K Sigmundsson; B-L Johansson; K Ekberg; G Alvelius; M Henriksson; J Johansson; J Wahren; H Jörnvall
Journal:  Cell Mol Life Sci       Date:  2006-08       Impact factor: 9.261

9.  Serum C peptide level and renal function in diabetes mellitus.

Authors:  M N Chowta; P M Adhikari; N K Chowta; A K Shenoy; S D'Souza
Journal:  Indian J Nephrol       Date:  2010-01

10.  Relationship between modified homeostasis model assessment/correlative serum factors and diabetic retinopathy among type 2 diabetics with insulin therapy in Guangzhou, China.

Authors:  Li Hu; Dong-Hao Li
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.